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fluticasone furoate/vilanterol and
umeclidinium/vilanterol in patients with
COPD: results on cardiovascular safety from
the IMPACT trial
Nicola C. Day1*, Subramanya Kumar1, Gerard Criner2, Mark Dransfield3, David M. G. Halpin4, MeiLan K. Han5,
C. Elaine Jones6, Morrys C. Kaisermann7, Sally Kilbride1, Peter Lange8,9, David A. Lomas10, Neil Martin11,12,
Fernando J. Martinez13, Dave Singh14, Robert Wise15 and David A. Lipson7,16Abstract
Background: This analysis of the IMPACT study assessed the cardiovascular (CV) safety of single-inhaler triple
therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI and UMEC/VI dual therapy.
Methods: IMPACT was a 52-week, randomized, double-blind, multicenter Phase III study comparing the efficacy
and safety of FF/UMEC/VI 100/62.5/25 mcg with FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg in patients ≥40 years of
age with symptomatic chronic obstructive pulmonary disease (COPD) and ≥1 moderate/severe exacerbation in the
previous year. The inclusion criteria for the study were intentionally designed to permit the enrollment of patients
with significant concurrent CV disease/risk. CV safety assessments included proportion of patients with and
exposure-adjusted rates of on-treatment CV adverse events of special interest (CVAESI) and major adverse cardiac
events (MACE), as well as time-to-first (TTF) CVAESI, and TTF CVAESI resulting in hospitalization/prolonged
hospitalization or death.
Results: Baseline CV risk factors were similar across treatment groups. Overall, 68% of patients (n = 7012) had ≥1 CV
risk factor and 40% (n = 4127) had ≥2. At baseline, 29% of patients reported a current/past cardiac disorder and
58% reported a current/past vascular disorder. The proportion of patients with on-treatment CVAESI was 11% for
both FF/UMEC/VI and UMEC/VI, and 10% for FF/VI. There was no statistical difference for FF/UMEC/VI versus FF/VI or
UMEC/VI in TTF CVAESI (hazard ratio [HR]: 0.98, 95% confidence interval [CI]: 0.85, 1.11; p = 0.711 and HR: 0.92, 95%
CI: 0.78, 1.08; p = 0.317, respectively) nor TTF CVAESI leading to hospitalization/prolonged hospitalization or death
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(HR: 1.19, 95% CI: 0.93, 1.51; p = 0.167 and HR: 0.96, 95% CI: 0.72, 1.27; p = 0.760, respectively). On-treatment MACE
occurred in ≤3% of patients across treatment groups, with similar prevalence and rates between treatments.
Conclusions: In a symptomatic COPD population with a history of exacerbations and a high rate of CV disease/risk,
the proportion of patients with CVAESI and MACE was 10–11% and 1–3%, respectively, across treatment arms, and
the risk of CVAESI was low and similar across treatment arms. There was no statistically significant increased CV risk
associated with the use of FF/UMEC/VI versus FF/VI or UMEC/VI, and UMEC/VI versus FF/VI.
Trial registration: NCT02164513 (GSK study number CTT116855).
Keywords: COPD, Triple therapy, LAMA/LABA, ICS/LABA, Cardiovascular safetyBackground
Chronic obstructive pulmonary disease (COPD) is a
common respiratory disease characterized by chronic
airflow limitation and persistent respiratory symptoms
[1]. COPD is associated with a substantial clinical bur-
den [1], was the third leading cause of death in the world
in 2016, and is expected to remain a leading cause of
death worldwide in 2030 [2, 3]. The main goals of COPD
pharmacological treatment are to reduce symptoms, im-
prove health status and exercise tolerance, and to reduce
the risk of exacerbation and mortality [1].
Most patients with COPD present with at least one
chronic comorbidity [4]. Clinicians must therefore take
into consideration the effect of therapeutic intervention
on comorbid diseases to ensure appropriate disease
management [1, 5]. Cardiovascular (CV) disease, includ-
ing coronary artery disease, heart failure, and arrhyth-
mias, is a common comorbidity of COPD [6].
Exacerbations in COPD symptoms are associated with
elevated CV disease risk or worse outcomes especially in
patients with concomitant COPD and CV disease [1, 6,
7]. Similarly, the presence of CV comorbidities in
patients with COPD has been associated with worse
outcomes [8].
COPD and CV disease share many risk factors, includ-
ing older age and history of smoking, as well as similar
pathophysiological mechanisms and exposures [6, 9].
Static and dynamic hyperinflation, which alter venous
return and cardiac output, hypoxemia, and systemic in-
flammation may each lead to increased risk of adverse
CV events/disease, which can then in turn exacerbate
COPD symptoms [6, 9–12].
Inhaled corticosteroids (ICS), long-acting β2-agonists
(LABA) and long-acting muscarinic antagonists (LAMA)
are a mainstay of COPD treatment [1]. There are con-
cerns that LAMA and LABA therapy may be associated
with a higher risk of cardiovascular adverse events, de-
pending on dosage and receptor specificity, by signaling
through β-adrenergic receptors and inhibiting muscar-
inic receptors, which are present in lung and heart tissue
[7, 13–15]. Some studies have suggested an increased
risk of CV events in patients with COPD receivingbronchodilators, although the evidence remains controver-
sial [7, 14, 16–18]. Recent studies have found no increased
CV risk with the use of inhaled COPD therapies or during
escalation from ICS/LABA to ICS/LAMA/LABA triple
therapy, but have noted that additional data are needed in
patients with higher CV risk [7, 19–21].
In the InforMing the Pathway of COPD Treatment
(IMPACT) study, once-daily single-inhaler triple therapy with
fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
reduced the rate of moderate/severe exacerbations and
improved lung function and health-related quality of
life compared with dual therapy with FF/VI or UMEC/VI
in patients ≥40 years of age with symptomatic COPD and
a history of exacerbations [22]. FF/UMEC/VI also
significantly reduced the rate of hospitalized exacerbations
and all-cause mortality versus UMEC/VI, with a reduction
in respiratory death, CV death, and death associated with
the patients’ underlying COPD when compared with
UMEC/VI [22].
Unlike many previous clinical studies, the IMPACT
trial had broad entry criteria and included patients with
significant concurrent CV disease/risk [23]. This allowed
the assessment of efficacy and CV safety of these inhaled
COPD therapies in a population that is more representative
of real-world clinical practice. The aim of this pre-specified
analysis was to assess the CV safety of FF/UMEC/VI
versus FF/VI and UMEC/VI in the intent-to-treat
(ITT) population of the IMPACT trial.
Methods
Study design
The IMPACT trial (GSK Study CTT116855;
NCT02164513) was a 52-week randomized, double-blind,
multicenter Phase III study, which compared the efficacy
and safety of once-daily single-inhaler triple therapy with
FF/UMEC/VI 100/62.5/25 mcg with once-daily dual
therapy with FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg.
The study design has been published previously [22, 23].
Briefly, after a 2-week run-in period during which patients
continued their existing COPD medications, patients were
randomized 2:2:1 to FF/UMEC/VI 100/62.5/25 mcg,
FF/VI 100/25 mcg or UMEC/VI 62.5/25 mcg, all
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inhaler.
Study population
Inclusion/exclusion criteria of the IMPACT trial have
been described previously [22]. Briefly, eligible patients
were ≥40 years of age with symptomatic COPD (COPD
Assessment Test score ≥10), and had a forced expiratory
volume in 1 s (FEV1) < 50% of predicted normal values
and a history of ≥1 moderate or severe exacerbation in
the previous year, or a FEV1 50–80% of predicted nor-
mal values and a history of ≥2 moderate or ≥1 severe ex-
acerbations in the previous year [22]. Patients were
excluded if they had unstable or life-threatening CV dis-
ease. However, patients with a history of previous myo-
cardial infarction (MI; >6 months prior to screening),
New York Heart Association (NYHA) Class 1–3 heart
failure, and unstable or life-threatening cardiac
arrhythmia requiring intervention (>3 months prior to
Screening) were eligible to participate in the study [23].
Patients using ≤3 L/min of supplemental oxygen at rest
at screening were also eligible to participate. The pres-
ence of CV risk factors was assessed at baseline, based
on data captured in the electronic case report form
(eCRF). Patients with ≥1 of the following past or current
medical conditions were classed as having a CV risk fac-
tor: angina pectoris, coronary artery disease, MI,
arrhythmia, congestive heart failure, hypertension, cere-
brovascular accident, carotid or aorto-femoral vascular
disease, diabetes mellitus, and hypercholesterolemia.
Study endpoints
Safety endpoints investigated in this analysis included
the incidence of investigator-reported adverse events
(AEs) of special interest (AESI), and the incidence of
major adverse cardiovascular events (MACE). AESI were
pre-specified groups of AEs of special interest for FF,
UMEC, or VI, or for patients with COPD, allowing for a
comprehensive review of safety data that is not limited
to a specific AE Preferred Term. For the AESI of Cardio-
vascular effects (termed CVAESI here), Standardized
Medical Dictionary for Regulatory Activities (MedDRA)
Queries (SMQs) were used. MedDRA SMQs are vali-
dated, pre-determined sets of MedDRA Preferred Terms
grouped together to facilitate the capture all plausible
events linked to a disease process [24]. In the IMPACT
study, CVAESI included cardiac arrhythmia (contains se-
lected sub-SMQs), cardiac failure (SMQ), ischemic heart
disease (SMQ), hypertension (SMQ), and central ner-
vous system (CNS) hemorrhages and cerebrovascular
conditions (SMQ). The CVAESI SMQs and constituent
Preferred Terms that were reported in the IMPACT
study are provided in Supplementary Table 1. Serious
CVAESI were those CVAESI reported as serious AEs(SAEs; as specified in the protocol [23]). CVAESI result-
ing in hospitalization/prolonged hospitalization or death
– referred to herein as ‘hospitalized or fatal CVAESI’ –
were classified as such according to investigator-
reported information in the eCRF.
MACE was determined from independently adjudi-
cated CV deaths and investigator-reported non-fatal AEs
and was broadly and narrowly defined. Broad MACE in-
cluded adjudicated CV deaths, non-fatal CNS hemor-
rhages and cerebrovascular conditions (SMQ), non-fatal
MI (SMQ) and non-fatal other ischemic heart disease
(SMQ). Narrow MACE included adjudicated CV deaths,
non-fatal CNS hemorrhages and cerebrovascular condi-
tions (SMQ), non-fatal MI Preferred Term and acute MI
Preferred Term.
On-treatment CV safety and MACE were assessed as
pre-specified analyses in the IMPACT study. On-
treatment CV safety assessments included: (1) the propor-
tion of patients with and exposure-adjusted rate of
CVAESI and serious CVAESI; (2) risk (time-to-first
[TTF]) of CVAESI; (3) risk (TTF) of hospitalized or fatal
CVAESI (overall and by baseline CV risk factors); and (4)
the proportion of patients with and exposure-adjusted rate
of MACE.
Statistical analyses
The proportion of patients with on-treatment MACE
was reported as a percentage and exposure-adjusted rate
per 1000-patient years. The risk of on-treatment
CVAESI and on-treatment hospitalized or fatal CVAESI
was evaluated using a TTF event analysis and derived
using a Cox proportional hazards model with covariates
of treatment group and geographical region.
Results
Patients
The ITT population included a total of 10,355 patients
(FF/UMEC/VI: N = 4151, FF/VI: N = 4134, UMEC/VI:
N = 2070) [22]. Baseline characteristics, CV disorders,
and risk factors were similar across treatment groups
(Table 1). At baseline, 29% (n = 2964) of patients reported
a current or past cardiac disorder (coronary artery disease
n = 1252 [12%]; arrhythmia n = 816 [8%]; angina pectoris
n = 737 [7%]; MI n = 681 [7%]; congestive heart failure
n = 539 [5%]). Overall, 58% (n = 6021) of patients reported
a current or past vascular disorder (hypertension n = 5446
[53%]; cerebrovascular accident n = 458 [4%]; carotid or
aorto-femoral vascular disease n = 342 [3%]).
Overall, 68% (n = 7012) of patients had at least one
CV risk factor and 40% (n = 4127) had at least 2
(Table 1). The reported frequency of risk factors was
consistent across treatment groups. The CV risk fac-
tors most frequently reported (≥10% of patients) were
hypertension (53%), hypercholesterolemia (33%),
Table 1 Baseline characteristics (ITT population)
FF/UMEC/VI
N = 4151
FF/VI
N = 4134
UMEC/VI
N = 2070
Overall
N = 10,355
Age, mean (SD), years 65.3 (8.2) 65.3 (8.3) 65.2 (8.3) 65.3 (8.3)
Gender, male, n (%) 2766 (67) 2748 (66) 1356 (66) 6870 (66)
BMI, mean (SD), kg/m2 26.6 (6.2) 26.7 (6.1) 26.6 (5.9) 26.6 (6.1)
Smoking status, n (%)
Current smoker 1436 (35) 1423 (34) 728 (35) 3587 (35)
Former smoker 2715 (65) 2711 (66) 1342 (65) 6768 (65)
Moderate or severe COPD exacerbations in previous year, n (%)
0 2 (< 1) 5 (< 1) 2 (< 1) 9 (< 1)
1 1853 (45) 1907 (46) 931 (45) 4691 (45)
2 1829 (44) 1768 (43) 890 (43) 4487 (43)
≥3 467 (11) 454 (11) 247 (12) 1168 (11)
Post-bronchodilator FEV1% predicted, mean (SD) 47.5 (15.0) 45.5 (14.8) 45.4 (14.7) 45.5 (14.8)
Current/past Cardiac disordersa, n (%) 1194 (29) 1173 (28) 597 (29) 2964 (29)
Current/past Vascular disordersa, n (%) 2362 (57) 2438 (59) 1221 (59) 6021 (58)
CV risk factorsa, n (%)
0 1365 (33) 1322 (32) 656 (32) 3343 (32)
1 1147 (28) 1158 (28) 580 (28) 2885 (28)
≥1 2786 (67) 2812 (68) 1414 (68) 7012 (68)
≥2 1639 (39) 1654 (40) 834 (40) 4127 (40)
CV risk factorsa, n (%)
Hypertension 2132 (51) 2207 (53) 1107 (53) 5446 (53)
Hypercholesterolemia 1354 (33) 1332 (32) 681 (33) 3367 (33)
Diabetes mellitus 641 (15) 645 (16) 313 (15) 1599 (15)
Coronary artery disease 510 (12) 488 (12) 254 (12) 1252 (12)
Arrhythmia 335 (8) 323 (8) 158 (8) 816 (8)
Angina pectoris 291 (7) 307 (7) 139 (7) 737 (7)
Myocardial infarction 270 (7) 274 (7) 137 (7) 681 (7)
Congestive heart failure 223 (5) 192 (5) 124 (6) 539 (5)
Cerebrovascular accident 199 (5) 165 (4) 94 (5) 458 (4)
Vascular diseaseb 133 (3) 148 (4) 61 (3) 342 (3)
Family history of CV risk factorsa, n (%)c
Premature coronary artery diseased
Yes 432 (10) 430 (10) 234 (11) 1096 (11)
No 3160 (76) 3097 (75) 1529 (74) 7786 (75)
Unknown 559 (13) 607 (15) 307 (15) 1473 (14)
Myocardial infarction
Yes 651 (16) 673 (16) 361 (17) 1685 (16)
No 3004 (72) 2954 (71) 1431 (69) 7389 (71)
Unknown 496 (12) 507 (12) 278 (13) 1281 (12)
Stroke
Yes 448 (11) 464 (11) 230 (11) 1142 (11)
No 3191 (77) 3150 (76) 1565 (76) 7906 (76)
Unknown 512 (12) 520 (13) 275 (13) 1307 (13)
aAs captured in the electronic case report form; bcarotid or aorto-femoral vascular disease; chistory in first degree relatives only; dwomen < 65 years-old,
men < 55 years-old.
BMI Body mass index; COPD Chronic obstructive pulmonary disease; CV Cardiovascular; FEV1 Forced expiratory volume in 1 s; FF Fluticasone furoate; ITT Intent-
to-treat; SD Standard deviation; UMEC Umeclidinium; VI Vilanterol
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(12%) (Table 1).
On-treatment CVAESI (defined by MedDRA SMQ [see
Supplementary Table 1])
The most frequently reported on-treatment AESI in the
ITT population was Cardiovascular Effects [22], referred
to in the current paper as CVAESI. The proportion of
patients with and exposure-adjusted rates of on-
treatment CVAESI were similar across all treatment
groups (proportion [rate per 1000 patient-years]: 11%
[167.2], 10% [157.0], and 11% [166.6] for FF/UMEC/VI,
FF/VI, and UMEC/VI, respectively) (Table 2). Cardiac
arrhythmia (comprised of sub-SMQs; Supplementary
Table 1) was reported most frequently and occurred in
a similar proportion of patients (4% in all treatment
groups) and with similar adjusted exposure rates across
treatment groups, followed by Cardiac failure (SMQ)
and Hypertension (SMQ), both of which occurred in 3%
of patients in all treatment groups (Table 2). Ischemic
heart disease (SMQ) occurred in 1–2% of patients
across treatment groups, with exposure-adjusted rates
for FF/UMEC/VI, FF/VI and UMEC/VI of 26.1, 18.5,
and 30.6 per 1000 patient-years, respectively (Table 2).
The proportion of patients with and rate of CVAESI
(including sub-SMQs) by baseline CV risk factors were
generally similar between treatment arms, with no pattern
of events observed (Supplementary Table 2).Table 2 Summary of on-treatment CVAESI by SMQs and sub-SMQs
Special interest group/subgroup FF/UM
(N = 41
Total duration at risk (patient-years) 3714.9
n (%)
CVAESIa 450 (1
Cardiac arrhythmia 153 (4)
Arrhythmia-related investigations, signs and symptoms (SMQ) 63 (2)
Bradyarrhythmia terms, nonspecific (SMQ) 0 (0)
Cardiac arrhythmia terms, nonspecific (SMQ) 7 (< 1)
Conduction defects (SMQ) 20 (< 1
Disorders of sinus node function (SMQ) 3 (< 1)
Supraventricular tachyarrhythmias (SMQ) 65 (2)
Tachyarrhythmia terms, nonspecific (SMQ) 3 (< 1)
Ventricular tachyarrhythmias (SMQ) 13 (< 1
Cardiac failure (SMQ) 138 (3)
CNS hemorrhages and cerebrovascular conditions (SMQ) 41 (< 1
Hypertension (SMQ) 113 (3)
Ischemic heart disease (SMQ) 80 (2)
#, number of events. Rates are reported as number of events per 1000 patient-year
risk. aNote, a patient may have experienced more than one CVAESI
CNS Central nervous system; CVAESI, Cardiovascular adverse event of special interes
Regulatory Activities; n Number of patients; SMQ Standardized MedDRA Query; UMEOn-treatment serious CVAESI occurred in 3–4% of
patients across treatment arms (Table 3). On-treatment
fatal serious CVAESI were reported in <1% of patients
in each treatment group, with exposure-adjusted rates
(per 1000 patient-years) of 7.0 for FF/UMEC/VI, 6.9 for
FF/VI, and 11.2 for UMEC/VI group.
Risk (TTF analysis) of on-treatment CVAESI
Based on an analysis of TTF event, the risk of experiencing
a CVAESI was similar for FF/UMEC/VI compared with
FF/VI (hazard ratio [HR]: 0.98, 95% CI: 0.85, 1.11; p = 0.711),
FF/UMEC/VI compared with UMEC/VI (HR: 0.92, 95% CI:
0.78, 1.08; p = 0.317) and UMEC/VI compared with FF/VI
(HR: 1.06, 95% CI: 0.90, 1.24; p = 0.490) (Figs 1 and 2).
The proportion of patients with hospitalized or fatal
CVAESI was 4, 3, and 3% for FF/UMEC/VI, FF/VI, and
UMEC/VI, respectively (Fig. 2a). There were no statisti-
cally significant differences in risk of hospitalized or fatal
CVAESI for FF/UMEC/VI versus FF/VI (HR: 1.19, 95%
CI: 0.93, 1.51; p = 0.167) or UMEC/VI (HR: 0.96, 95%
CI: 0.72, 1.27; p = 0.760), and UMEC/VI versus FF/VI
(HR: 1.24, 95% CI: 0.92, 1.66; p = 0.153) in the overall ITT
population (Figs. 2 and 3). A numerical increased risk of
hospitalized or fatal CVAESI was seen with FF/UMEC/VI
and UMEC/VI compared with FF/VI (Fig. 2).
There were no statistically significant differences in
the risk of hospitalized or fatal CVAESI between the
treatment groups when assessed by CV risk factor(ITT population)
EC/VI
51)
FF/VI
(N = 4134)
UMEC/VI
(N = 2070)
3457.9 1698.3
Rate [#] n (%) Rate [#] n (%) Rate [#]
1) 167.2 [621] 430 (10) 157.0 [543] 224 (11) 166.6 [283]
50.9 [189] 161 (4) 51.5 [178] 81 (4) 51.2 [87]
19.7 [73] 71 (2) 22.8 [79] 33 (2) 20.6 [35]
0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
1.9 [7] 10 (< 1) 2.9 [10] 6 (< 1) 3.5 [6]
) 5.7 [21] 16 (< 1) 4.6 [16] 10 (< 1) 5.9 [10]
0.8 [3] 2 (< 1) 0.6 [2] 0 (0) 0 [0]
18.8 [70] 51 (1) 15.9 [55] 27 (1) 16.5 [28]
0.8 [3] 4 (< 1) 1.2 [4] 1 (< 1) 0.6 [1]
) 3.5 [13] 13 (< 1) 3.8 [13] 7 (< 1) 4.1 [7]
42.5 [158] 126 (3) 42.8 [148] 68 (3) 44.8 [76]
) 12.1 [45] 28 (< 1) 9.3 [32] 11 (< 1) 6.5 [11]
35.5 [132] 115 (3) 35.0 [121] 54 (3) 34.2 [58]
26.1 [97] 57 (1) 18.5 [64] 47 (2) 30.6 [52]
s, calculated as the number of events × 1000, divided by the total duration at
t; FF Fluticasone furoate; ITT Intent-to-treat; MedDRA Medical Dictionary for
C Umeclidinium; VI Vilanterol
Table 3 Summary of on-treatment serious and fatal serious CVAESIa by SMQs and sub-SMQs (ITT population)
Special interest group/subgroup FF/UMEC/VI
(N = 4151)
FF/VI
(N = 4134)
UMEC/VI
(N = 2070)
Total duration at risk (patient-years) 3714.9 3457.9 1698.3
n (%) Rate [#] n (%) Rate [#] n (%) Rate [#]
Serious CVAESIb 151 (4) 54.1 [201] 119 (3) 38.2 [132] 74 (4) 51.2 [87]
Cardiac arrhythmia 47 (1) 15.1 [56] 40 (< 1) 11.9 [41] 27 (1) 17.1 [29]
Arrhythmia-related investigations, signs and symptoms (SMQ) 22 (< 1) 5.9 [22] 17 (< 1) 5.2 [18] 14 (< 1) 8.2 [14]
Bradyarrhythmia terms, nonspecific (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Cardiac arrhythmia terms, nonspecific (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Conduction defects (SMQ) 1 (< 1) 0.3 [1] 1 (< 1) 0.3 [1] 3 (< 1) 1.8 [3]
Disorders of sinus node function (SMQ) 1 (< 1) 0.3 [1] 1 (< 1) 0.3 [1] 0 (0) 0 [0]
Supraventricular tachyarrhythmias (SMQ) 26 (< 1) 7.8 [29] 16 (< 1) 4.6 [16] 9 (< 1) 5.3 [9]
Tachyarrhythmia terms, nonspecific (SMQ) 1 (< 1) 0.3 [1] 0 (0) 0 [0] 1 (< 1) 0.6 [1]
Ventricular tachyarrhythmias (SMQ) 2 (< 1) 0.5 [2] 5 (< 1) 1.4 [5] 2 (< 1) 1.2 [2]
Cardiac failure (SMQ) 45 (1) 14.8 [55] 33 (< 1) 9.8 [34] 15 (< 1) 10.6 [18]
CNS hemorrhages and cerebrovascular conditions (SMQ) 32 (< 1) 9.4 [35] 20 (< 1) 6.1 [21] 7 (< 1) 4.1 [7]
Hypertension (SMQ) 6 (< 1) 1.6 [6] 4 (< 1) 1.2 [4] 2 (< 1) 1.2 [2]
Ischemic heart disease (SMQ) 44 (1) 13.2 [49] 32 (< 1) 9.3 [32] 29 (1) 18.3 [31]
Fatal serious CVAESIb 21 (< 1) 7.0 [26] 24 (< 1) 6.9 [24] 19 (< 1) 11.2 [19]
Cardiac arrhythmia 12 (< 1) 3.8 [4] 9 (< 1) 2.6 [9] 11 (< 1) 6.5 [11]
Arrhythmia-related investigations, signs and symptoms (SMQ) 11 (< 1) 3.0 [11] 8 (< 1) 2.3 [8] 10 (< 1) 5.9 [10]
Bradyarrhythmia terms, nonspecific (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Cardiac arrhythmia terms, nonspecific (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Conduction defects (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Disorders of sinus node function (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Supraventricular tachyarrhythmias (SMQ) 2 (< 1) 0.5 [2] 0 (0) 0 [0] 1 (< 1) 0.6 [1]
Tachyarrhythmia terms, nonspecific (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Ventricular tachyarrhythmias (SMQ) 2 (< 1) 0.5 [2] 0 (0) 0 [0] 1 (< 1) 0.6 [1]
Cardiac failure (SMQ) 4 (< 1) 1.1 [4] 6 (< 1) 1.7 [6] 3 (< 1) 1.8 [3]
CNS hemorrhages and cerebrovascular conditions (SMQ) 3 (< 1) 1.3 [5] 7 (< 1) 2.0 [7] 1 (< 1) 0.6 [1]
Hypertension (SMQ) 0 (0) 0 [0] 0 (0) 0 [0] 0 (0) 0 [0]
Ischemic heart disease (SMQ) 3 (< 1) 0.8 [3] 2 (< 1) 0.6 [2] 4 (< 1) 2.4 [4]
aSerious as specified in the study protocol [23]; bNote, a patient may have experienced more than one CVAESI (including those that led to a fatal outcome). #,
number of events. Rates are reported as number of events per 1000 patient-years, calculated as the number of events × 1000, divided by the total duration at risk
CNS Central nervous system; CVAESI Cardiovascular adverse event of special interest; FF Fluticasone furoate; ITT Intent-to-treat; MedDRA Medical Dictionary for
Regulatory Activities; n Number of patients; SMQ Standardized MedDRA Query; UMEC Umeclidinium; VI Vilanterol
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of hospitalized or fatal CVAESI with FF/UMEC/VI
compared with FF/VI was seen in patients who had
no CV risk factors at baseline.
Prevalence and rates of on-treatment MACE
The proportion of patients with and exposure-adjusted rates
for any on-treatment MACE using the broad and narrow
definitions were similar across treatment groups, with no
consistent pattern seen between individual MACE categories
(Table 4). The proportion of patients with MACE using the
narrow definition was 2, 1, and 2% for FF/UMEC/VI, FF/VI,and UMEC/VI, respectively, with exposure-adjusted rates of
22.3, 18.8, and 22.4 per 1000 patient-years (Table 4). The
proportion of patients with MACE using the broad definition
was 3, 2, and 3% for FF/UMEC/VI, FF/VI, and UMEC/VI,
respectively. The broad MACE exposure-adjusted rate was
44.7, 35.3, and 44.8 per 1000 patient-years for FF/UMEC/VI,
FF/VI, and UMEC/VI, respectively (Table 4). The proportion
of patients with adjudicated CV deaths was low across all
treatment groups (<1%), with numerically lower exposure-
adjusted rates observed in the FF/UMEC/VI and FF/VI
groups (5.4 and 7.8 respectively) compared with the
UMEC/VI group (9.4) (Table 4).
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IMPACT was a large trial in patients with symptomatic
COPD and at risk of exacerbation evaluating the efficacy
and safety of triple ICS/LAMA/LABA therapy versus
dual LAMA/LABA or ICS/LABA therapy using the same
molecules, doses and delivery device. The study hadOn-treatment CVAESI
FF/UMEC/VI vs FF/VI
FF/UMEC/VI vs UMEC/VI
On-treatment CVAESI leading to
hospitalization/prolonged hospitalization or death 
FF/UMEC/VI vs FF/VI
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0.6
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Fig. 2 TTF on-treatment CVAESI and hospitalized or fatal CVAESI. a. FF/UME
or fatal CVAESI refers to any CVAESI that resulted in hospitalization/prolong
cardiovascular adverse event of special interest; FF, fluticasone furoate; n, n
TTF, time to first; UMEC, umeclidinium; VI, vilanterolbroad inclusion criteria, in particular with regards to sig-
nificant concurrent CV disease/risk [22], compared with
previously reported randomized controlled trials. In the
IMPACT trial, patients with significant pre-existing CV
disease were included and, therefore, the trial population
is more likely to accurately reflect the real-world COPD0.98 (0.85, 1.11)
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CV risk factor, and 40% had at least two. Approximately
half of the patients across all treatment groups presented
with vascular disorders at baseline and 16% had cardiac
disorders.
This study shows that, in this symptomatic COPD
population with a history of exacerbations including ap-
proximately two-thirds of patients with at least one CV
risk factor at baseline, the proportion of patients with on-
treatment CVAESI was 10–11% and with on-treatment
MACE was 1–3%, without a consistent pattern across
treatment groups. Furthermore, although the IMPACTNo CV risk factors
FF/UMEC/VI vs FF/VI
FF/UMEC/VI vs UMEC/VI
1 CV risk factor
FF/UMEC/VI vs FF/VI
FF/UMEC/VI vs UMEC/VI
24/1365 (2)
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97/1639 (6)
78/1654 (5)
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0.0
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Fig. 4 TTF on-treatment hospitalized or fatal CVAESI according to CV risk fa
fatal CVAESI refers to any CVAESI that resulted in hospitalization/prolonged
CVAESI, cardiovascular adverse event of special interest; FF, fluticasone furo
subgroup; TTF, time to first; UMEC, umeclidinium; VI, vilanterolstudy was not powered to assess CV safety, a low risk of
on-treatment CVAESI was seen and there was no statisti-
cally significant increase in the risk of CVAESI, or hospi-
talized or fatal CVAESI, with FF/UMEC/VI versus either
dual therapy; this was consistently observed irrespective of
the number of baseline CV risk factors. There was a non-
statistically significant increase in the risk of hospitalized
or fatal CVAESI with FF/UMEC/VI and UMEC/VI com-
pared with FF/VI. In addition, in patients who had no CV
risk factors at baseline, there was a non-statistically signifi-
cant increase in the risk of hospitalized or fatal CVAESI
with FF/UMEC/VI compared with FF/VI.1.69 (0.86, 3.32)
1.35 (0.61, 3.01)
1.02 (0.60, 1.72)
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ctors*. *In ≥3% of patients in any treatment group. Hospitalized or
hospitalization or death. CI, confidence interval; CV, cardiovascular;
ate; n, number of patients with an event; N, number of patients in
Table 4 On-treatment MACE (ITT population)
FF/UMEC/VI
(N = 4151)
FF/VI
(N = 4134)
UMEC/VI
(N = 2070)
Total duration at risk (patient-years) 3714.9 3457.9 1698.3
n (%) Rate [#] n (%) Rate [#] n (%) Rate [#]
Narrow definition
Any MACE 80 (2) 22.3 [83] 60 (1) 18.8 [65] 37 (2) 22.4 [38]
Adjudicated CV death 20 (< 1) 5.4 [20] 27 (< 1) 7.8 [27] 16 (< 1) 9.4 [16]
Non-fatal CNS hemorrhages and cerebrovascular conditions (SMQ) 38 (< 1) 10.8 [40] 21 (< 1) 7.2 [25] 10 (< 1) 5.9 [10]
Non-fatal MI (PT) 9 (< 1) 2.4 [9] 6 (< 1) 1.7 [6] 5 (< 1) 2.9 [5]
Non-fatal acute MI (PT) 13 (< 1) 3.8 [14] 7 (< 1) 2.0 [7] 7 (< 1) 4.1 [7]
Broad definition
Any MACE 133 (3) 44.7 [166] 100 (2) 35.3 [122] 66 (3) 44.8 [76]
Adjudicated CV death 20 (< 1) 5.4 [20] 27 (< 1) 7.8 [27] 16 (< 1) 9.4 [16]
Non-fatal CNS hemorrhages and cerebrovascular conditions (SMQ) 38 (< 1) 10.8 [40] 21 (< 1) 7.2 [25] 10 (< 1) 5.9 [10]
Non-fatal MI (SMQ) 49 (1) 14.0 [52] 29 (< 1) 9.3 [32] 24 (1) 14.7 [25]
Non-fatal other ischemic heart disease (SMQ) 41 (< 1) 14.5 [54] 32 (< 1) 11.0 [38] 25 (1) 14.7 [25]
#, number of events. Rates are reported as number of events per 1000 patient-years, calculated as the number of events × 1000, divided by the total duration
at risk
CNS Central nervous system; CV Cardiovascular; FF Fluticasone furoate; ITT Intent-to-treat; MACE Major adverse cardiac event; MedDRA Medical Dictionary for
Regulatory Activities; MI Myocardial infarction; n, number of patients; PT Preferred Term; SMQ Standardized MedDRA Query; UMEC Umeclidinium; VI Vilanterol
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treatment CVAESI and serious CVAESI, as well as narrow
and broad MACE were small between the FF/UMEC/VI
group and the FF/VI and UMEC/VI dual therapy
groups. Any observed differences were likely due to
the small number of events rather than an effect of
the drug itself.
The exposure-adjusted rate of on-treatment CVAESI
observed in the IMPACT trial should also be viewed
in the context of using AESI for assessing CV safety
outcomes. The use of CVAESI is a more conservative
approach than using individual CV AE Preferred
Terms or MACE, since the CVAESI encompasses a
broad list of CV AE Preferred Terms that are pre-
defined by the MedDRA. Furthermore, the IMPACT
trial population reflects a population with a heavy CV
risk factor burden when compared with the general
COPD population as reported in a pooled analysis of
the National Health and Nutrition Examination Sur-
veys (NHANES) data [25], suggesting that the benefit
seen with FF/UMEC/VI may extend outside the
clinical trial environment.
Recent studies including meta-analyses and systematic
reviews have demonstrated no increased CV risk dur-
ing escalation from LAMA or LABA monotherapy to
dual LAMA/LABA therapy, nor from ICS/LABA to
ICS/LAMA/LABA triple therapy [7, 19, 20, 26, 27];
however, patients with high CV risk were not specifically
included in some of these studies. The studies published
so far have not highlighted CV safety concerns for UMEC
[15], although, results are awaited from an ongoingobservational study specifically investigating the effect of
UMEC/VI versus tiotropium (TIO) on CV safety [28].
In a 2018 case-control study investigating dual
LAMA/LABA therapy in more than 280,000 patients
with COPD in Taiwan, a 1.5-fold increase of severe CV
risk was demonstrated in patients who were naïve to
LAMA/LABA treatment compared with patients who
had prior exposure, regardless of exacerbation history or
CV disease status [29]. However, this effect was only ob-
served within 30 days of the onset of treatment; beyond
30 days of treatment the risk waned and subsequently
reached lower than baseline levels [29]. As such, these
results should be interpreted with caution, since if the
increased risk of CV events was truly treatment-related
the effect seen would be expected to continue beyond
30 days. This may reflect misdiagnosis, with cardiac
symptoms being mistaken for COPD-related symptoms.
Alternatively, it may suggest that this study was con-
founded by indication, as the study evaluated patients
who newly initiated LAMA/LABA, i.e., likely to be
symptomatic and requiring maximal bronchodilation
due to the severity of their COPD; these patients would
therefore be unstable and likely to be at a higher risk of
experiencing adverse CV events [6].
Other clinical trials of single-inhaler triple therapy
with ICS/LAMA/LABA have also shown similar CV
safety profiles for triple therapy compared with LAMA
monotherapy or ICS/LABA therapy. The TRILOGY
(NCT01917331), TRINITY (NCT01911364), and TRIB-
UTE (NCT02579850) studies compared single-inhaler
beclomethasone dipropionate/formoterol fumarate/
Day et al. Respiratory Research          (2020) 21:139 Page 10 of 12glycopyrronium bromide triple therapy versus beclomethasone
dipropionate/formoterol fumarate (ICS/LABA), TIO, and
beclomethasone dipropionate/formoterol fumarate + TIO
in multiple inhalers, and indacaterol/glycopyrronium
(LABA/LAMA) over 52 weeks [30–32]. These studies
showed similar prevalence of CV AEs and SAEs (e.g.,
ischemic heart disease and cardiac failure) and MACE
between single-inhaler triple therapy and comparator
arms [30–32]. However, these studies excluded patients
with clinically significant CV disease, such as unstable
ischemic heart disease, NYHA Class 3/4, left ventricular
failure and acute MI, and patients with atrial fibrillation
[30–32]. In contrast, the IMPACT study was designed
with broader inclusion criteria with regards to CV disease
and permitted participation of patients with history of
previous MI (>6 months prior to screening), NYHA
Class 1–3 heart failure, and unstable or life-
threatening cardiac arrhythmia requiring intervention
(>3 months prior to Screening) [22]. The IMPACT
study results therefore support and expand the find-
ings from other studies of triple therapies and those
from recent meta-analyses and systematic reviews
which demonstrated no increased CV risk with the
use of inhaled COPD therapies [7, 19, 20]. These
findings also support the overall favorable CV safety
profile of FF/UMEC/VI triple therapy for the treatment of
patients with symptomatic COPD and a history of exacer-
bations and are consistent with the extensive CV safety
database for FF/VI, UMEC/VI, and UMEC monotherapy.
The data presented within this analysis, however,
should be interpreted within the context of some poten-
tial limitations. Firstly, the study was not primarily de-
signed or statistically powered for specifically assessing
CV safety; secondly, the number of patients presenting
with CV events was relatively small; and thirdly, the
study duration of 52 weeks is short compared with
studies dedicated to investigating CV outcomes.
In the IMPACT study, FF/UMEC/VI significantly re-
duced the rate of severe exacerbations compared with
both dual therapies [22]. A post hoc analysis of the
SUMMIT (NCT01313676) study data has shown that
COPD exacerbations can increase the risk of CV events
[9], and other studies have shown that CV involvement
during a COPD exacerbation may contribute to poor
outcomes [33, 34]. The greater reduction in the rate and
risk of exacerbations observed with FF/UMEC/VI com-
pared with either dual therapy in the IMPACT trial [22]
may therefore be expected to reduce the risk of CV mor-
tality. The IMPACT trial demonstrated a significant 28%
reduction in on−/off-treatment all-cause mortality with
FF/UMEC/VI versus UMEC/VI and a non-statistically
significant reduction of 11% versus FF/VI, although CV
mortality has not been specifically assessed [35, 36]. As
the current analysis is focused on all CVAESI and onlyincludes on-treatment events, it would be of interest to
further explore the relationship between CV events,
COPD exacerbations, and mortality in IMPACT in future
analyses.Conclusions
In a large symptomatic COPD population with a history
of exacerbations and a high rate of CV disease/risk, the
proportion of patients with on-treatment CVAESI and
MACE was 10–11% and 1–3%, respectively, and the risk
of on-treatment CVAESI was low, with no consistent
patterns across triple and dual treatment groups. These
results for FF/UMEC/VI show no additive CV risk with
bronchodilator combinations and are consistent with a
previous network meta-analysis [37] and with the exten-
sive existing CV safety database for FF/VI, UMEC/VI,
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